ARTICLE | Top Story
Hedge fund targets Exact Sciences' Cologuard
July 1, 2015 1:41 AM UTC
CMS has placed Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) on the agenda of a July 16 (see BioCentury Extra, Oct. 9, 2014).
In a September 2014 letter to CMS, Cable Car Capital portfolio manager Jacob Ma-Weaver said the NCD should be modified to lengthen the screening interval and cover only beneficiaries aged 50-75, the age range recommended for screening by the U.S. Preventive Services Task Force. In a second letter to the agency in October 2014, Ma-Weaver urged CMS to reconsider the reimbursement rate for Cologuard, arguing that any reimbursement above a range of $80-$191 "should require a very compelling justification." ...